Drug Approval | November 24, 2023
Lupin receives tentative approval from USFDA for Canagliflozin Tablets
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
The Product will be manufactured at the company's facility in Bengaluru
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
The product will be manufactured at Lupin’s Nagpur facility in India
Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Subscribe To Our Newsletter & Stay Updated
